Despite recommendations and the passage of legislation, there is little evidence that the quality of behavioral health has improved significantly over the last 10 years in the United States.
Ten years ago the Institute of Medicine (IOM) issued a report that made bold recommendations to improve the quality of behavioral health care in the United States, but few of them have been implemented.
According to a recently published overview in the June 2016 issue of Health Affairs, even with the enactment of the Affordable Care Act (ACA), the passage of legislation in 2008 requiring parity of insurance coverage for behavioral and physical health, and greater recognition of the effect behavioral health disorders have on the population’s health, there is little evidence that the quality of behavioral health has improved significantly over the last 10 years. This is the case even though reforms have brought expanded resources and requirements for assessing quality, and provided an increased number of state and nongovernmental organizations charged with focusing on developing and implementing quality measures for behavioral health.
Harold Alan Pincus, MD, of the Department of Psychiatry, College of Physicians and Surgeons at Columbia University in New York City, and colleagues provided an overview of the current state of quality measurement in behavioral health, and make recommendations as to how to develop a set of measures for behavioral health quality that are as robust as those for general medical conditions.
For example, the authors wrote, the average performance on 4 behavioral health measures among commercial plans reported in 2014 was 48% compared with an average of 72% for 6 cardiovascular and diabetes measures. These findings meant that, on average, people with mental health or substance use needs get recommended care half the time, while recommended care occurs about two-thirds of the time for people with diabetes or hypertension. The patterns were the same in Medicare and Medicaid, research suggested.
The authors highlight the following 5 key priorities that need to be addressed:
The authors concluded that in order to move from measurement to improvement of behavioral healthcare, there must be national leadership and coordination in terms of what entities are responsible for supporting and funding the science of developing quality measurement and improvement strategies.
Stronger collaboration between funding agencies is needed. Data sources must be linked, including better adoption of electronic health records, which has lagged in behavioral health settings. Finally, a well-prepared workforce must be trained and held accountable for improving quality and outcomes for individuals with behavioral health conditions.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More